Bacterial genomes and vaccine design

Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines

Volumn , Issue , 2013, Pages 13-37

  Cafardi, Valeria ^a   Telford, John L ^a   Serruto, Davide ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949290313     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5070-2_2     Document Type: Chapter

References (80)

1. Fleischmann RD et al (1995) Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269(5223):496-512
2. Medini D et al (2008) Microbiology in the post-genomic era. Nat Rev Microbiol 6(6):419-430
3. Raskin DM et al (2006) Bacterial genomics and pathogen evolution. Cell 124(4):703-714
4. Rappuoli R (2001) Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19(17-19):2688-2691
5. Stephens DS, Greenwood B, Brandtzaeg P (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369(9580):2196-2210
6. Caugant DA, Maiden MC (2009) Meningococcal carriage and disease-population biology and evolution. Vaccine 27(suppl 2):B64-B70
7. Tettelin H et al (2000) Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287(5459):1809-1815
8. Pizza M et al (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459):1816-1820
9. Borrow R, Balmer P, Miller E (2005) Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23(17-18):2222-2227
10. Goldschneider I, Gotschlich EC, Artenstein MS (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129(6):1307-1326
11. Serruto D et al (2010) Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 107(8):3770-3775
12. Masignani V et al (2003) Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197(6):789-799
13. Seib KL et al (2009) Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77(1):292-299
14. Capecchi B et al (2005) Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 55 (3):687-698
15. Comanducci M et al (2002) NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 195(11):1445-1454
16. Giuliani MM et al (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 103(29):10834-10839
17. Kimura A et al (2011) Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 18(3):483-486
18. Findlow J et al (2010) Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 51(10):1127-1137
19. Snape MD et al (2010) Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J 29(12):e80-e90
20. Johri AK et al (2006) Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol 4(12):932-942
21. Tettelin H et al (2002) Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci USA 99 (19):12391-12396
22. Tettelin H et al (2005) Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci USA 102(39):13950-13955
23. Maione D et al (2005) Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science 309(5731):148-150
24. Lauer P et al (2005) Genome analysis reveals pili in Group B Streptococcus. Science 309 (5731):105
25. Rosini R et al (2006) Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol 61(1):126-141
26. Margarit I et al (2009) Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 199(1):108-115
27. Brzuszkiewicz E et al (2006) How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains. Proc Natl Acad Sci USA 103 (34):12879-12884
28. Hain T et al (2007) Pathogenomics of Listeria spp. Int J Med Microbiol 297(7-8):541-557
29. Perrin A et al (2002) Comparative genomics identifies the genetic islands that distinguish Neisseria meningitidis, the agent of cerebrospinal meningitis, from other Neisseria species. Infect Immun 70(12):7063-7072
30. Perrin A, Nassif X, Tinsley C (1999) Identification of regions of the chromosome of Neisseria meningitidis and Neisseria gonorrhoeae which are specific to the pathogenic Neisseria species. Infect Immun 67(11):6119-6129
31. Moriel DG et al (2010) Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci USA 107 (20):9072-9077
32. Madico G et al (2007) Factor H binding and function in sialylated pathogenic neisseriae is influenced by gonococcal, but not meningococcal, porin. J Immunol 178(7):4489-4497
33. Schneider MC et al (2007) Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 15(5):233-240
34. Telford JL et al (2006) Pili in gram-positive pathogens. Nat Rev Microbiol 4(7):509-519
35. Barocchi MA et al (2006) A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci USA 103(8):2857-2862
36. Mora M et al (2005) Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci USA 102(43):15641-15646
37. Adu-Bobie J et al (2003) Two years into reverse vaccinology. Vaccine 21(7-8):605-610
38. Bambini S et al (2009) Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27 (21):2794-2803
39. Donnelly J et al (2010) Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 107 (45):19490-19495
40. Telford JL (2008) Bacterial genome variability and its impact on vaccine design. Cell Host Microbe 3(6):408-416
41. Hall N (2007) Advanced sequencing technologies and their wider impact in microbiology. J Exp Biol 210(Pt 9):1518-1525
42. Schuster SC (2008) Next-generation sequencing transforms today's biology. Nat Methods 5 (1):16-18
43. Margulies M et al (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437(7057):376-380
44. Bennett ST et al (2005) Toward the 1,000 dollars human genome. Pharmacogenomics 6 (4):373-382
45. Shendure J et al (2005) Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309(5741):1728-1732
46. Ansorge WJ (2009) Next-generation DNA sequencing techniques. N Biotechnol 25 (4):195-203
47. Metzker ML (2010) Sequencing technologies-the next generation. Nat Rev Genet 11 (1):31-46
48. Harris SR et al (2010) Evolution of MRSA during hospital transmission and intercontinental spread. Science 327(5964):469-474
49. Croucher NJ et al (2011) Rapid pneumococcal evolution in response to clinical interventions. Science 331(6016):430-434
50. Grifantini R et al (2002) Previously unrecognized vaccine candidates against group B meninococcus identified by DNA microarrays. Nat Biotechnol 20(9):914-921
51. Wizemann TM et al (2001) Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 69 (3):1593-1598
52. Hoskins J et al (2001) Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol 183(19):5709-5717
53. Etz H et al (2002) Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 99(10):6573-6578
54. Vytvytska O et al (2002) Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis. Proteomics 2(5):580-590
55. Ross BC et al (2001) Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine 19(30):4135-4142
56. Hughes MJ et al (2002) Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun 70(3):1254-1259
57. Reid SD et al (2002) Postgenomic analysis of four novel antigens of group a streptococcus: growth phase-dependent gene transcription and human serologic response. J Bacteriol 184 (22):6316-6324
58. Rodriguez-Ortega MJ et al (2006) Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 24 (2):191-197
59. Montigiani S et al (2002) Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun 70(1):368-379
60. Berlanda Scorza F et al (2008) Proteomics characterization of outer membrane vesicles from the extraintestinal pathogenic Escherichia coli DeltatolR IHE3034 mutant. Mol Cell Proteoics 7(3):473-485
61. Serruto D et al (2004) Biotechnology and vaccines: application of functional genomics to Neisseria meningitidis and other bacterial pathogens. J Biotechnol 113(1-3):15-32
62. Sorek R, Cossart P (2010) Prokaryotic transcriptomics: a new view on regulation, physiology and pathogenicity. Nat Rev Genet 11(1):9-16
63. Croucher NJ, Thomson NR (2010) Studying bacterial transcriptomes using RNA-seq. Curr Opin Microbiol 13(5):619-624
64. Yoder-Himes DR et al (2009) Mapping the Burkholderia cenocepacia niche response via highthroughput sequencing. Proc Natl Acad Sci USA 106(10):3976-3981
65. Perkins TT et al (2009) A strand-specific RNA-Seq analysis of the transcriptome of the typhoid bacillus Salmonella typhi. PLoS Genet 5(7):e1000569
66. Mraheil MA et al (2011) The intracellular sRNA transcriptome of Listeria monocytogenes during growth in macrophages. Nucleic Acids Res 39(10):4235-4248
67. Passalacqua KD et al (2009) Structure and complexity of a bacterial transcriptome. J Bacteriol 191(10):3203-3211
68. Camarena L et al (2010) Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. PLoS Pathog 6(4):e1000834
69. Albrecht M et al (2010) Deep sequencing-based discovery of the Chlamydia trachomatis transcriptome. Nucleic Acids Res 38(3):868-877
70. Sharma CM et al (2010) The primary transcriptome of the major human pathogen Helicobacter pylori. Nature 464(7286):250-255
71. Mahan MJ, Slauch JM, Mekalanos JJ (1993) Selection of bacterial virulence genes that are specifically induced in host tissues. Science 259(5095):686-688
72. Hensel M et al (1995) Simultaneous identification of bacterial virulence genes by negative selection. Science 269(5222):400-403
73. Sun YH et al (2000) Functional genomics of Neisseria meningitidis pathogenesis. Nat Med 6 (11):1269-1273
74. van Opijnen T, Bodi KL, Camilli A (2009) Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms. Nat Methods 6(10):767-772
75. van Opijnen, T. and A. Camilli, Genome-wide fitness and genetic interactions determined by Tn-seq, a high-throughput massively parallel sequencing method for microorganisms. Curr Protoc Microbiol, 2010. Chapter 1: p. Unit1E 3.
76. Langridge GC et al (2009) Simultaneous assay of every Salmonella Typhi gene using one million transposon mutants. Genome Res 19(12):2308-2316
77. Gawronski JD et al (2009) Tracking insertion mutants within libraries by deep sequencing and a genome-wide screen for Haemophilus genes required in the lung. Proc Natl Acad Sci USA 106(38):16422-16427
78. Rappuoli R (2004) From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med 10(11): 1177-85
79. Granoff DM et al. (2009) Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77(2): 764-9
80. Metruccio MM et al (2009) A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog 5(12): e1000710